Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge.
calciphylaxis
fgfr
fgfr2
fgfr2 inhibitor
hyperphosphatemia
pemigatinib
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
13
01
2022
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Specific fibroblast growth factor receptor (FGFR) inhibitors have been developed to treat malignancies harboring fusions or rearrangements in FGFR2 or FGFR3. Here, we report a case of calciphylaxis cutis in association with FGFR inhibitor therapy in a patient with FGFR2 rearranged cholangiocarcinoma. Although calciphylaxis cutis typically arises in the setting of hyperphosphatemia and end-stage renal disease, this patient had preserved renal function, normal serum calcium, and only modestly elevated serum phosphorus levels, which is similar to other recent reports of calciphylaxis in patients receiving FGFR inhibitor therapy. Calciphylaxis cutis is a possible adverse event observed with FGFR inhibitor therapy, and the mechanism of calciphylaxis cutis in association with FGFR inhibitor therapy warrants further investigation.
Identifiants
pubmed: 35223258
doi: 10.7759/cureus.21478
pmc: PMC8860720
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e21478Subventions
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Informations de copyright
Copyright © 2022, Griffith et al.
Déclaration de conflit d'intérêts
The authors have declared financial relationships, which are detailed in the next section.
Références
N Engl J Med. 2018 May 03;378(18):1704-1714
pubmed: 29719190
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Oncologist. 2021 Feb;26(2):e316-e326
pubmed: 33021006
JAMA Dermatol. 2021 Jan 1;157(1):119-121
pubmed: 33052389
J Cutan Pathol. 2018 Oct;45(10):786-790
pubmed: 30021048
N Engl J Med. 2008 Aug 7;359(6):584-92
pubmed: 18687639
JAAD Case Rep. 2020 Dec 02;7:125-127
pubmed: 33426250